PPT-Selecting Therapy for Relapsed/

Refractory Multiple Myeloma Case 1 Monitoring PostASCT Blood Testing Other Monitoring After Initial Therapy Case 1 cont Assessment at Relapse Symptomatic First Relapse Cytogenetic Testing at Relapse. With a Short First Remission:. How Aggressive Should We Be?. Carla Casulo, MD. Wilmot Cancer Institute. University of Rochester Medical Center. Rochester, New York . Lymphoma & Myeloma 2014: An International Congress on Hematologic Malignancies. Agents . for . Indolent . L. ymphoma . and . Mantle Cell Lymphoma. . Stephen Ansell, MD, PhD. Mayo Clinic. Tiacci. et al, Nature . Reviews Cancer 6, 437-. 448, 2006.. Would we expect mantle cell lymphoma and follicular lymphoma to respond to similar agents?. Topics. Current Treatment Options for Relapsed/Refractory Multiple Myeloma. Topics. Relapsed/Refractory MM. Treatment Goals and Strategies. Relapsed/Refractory MM. Exposure to Stem Cell Toxic Agents Not An Issue for Most Patients . 1. 6.01U SELECTING FOOD. 1. 6.01U Selecting Food. 2. Canned Food. Look for undented, nonbulging, rustfree cans. Check for sell-by or expiration dates. 6.01U Selecting Food. 3. Boxed/Packaged Food. 5 Multiple Myeloma SANDRA E. KURTIN, RN, MS, AOCN Ruben Niesvizky. Myeloma Center. Myelomacenter.org. run9001@med.cornell.edu. Multiple Myeloma: Natural History of Disease. Durie B; International Myeloma Foundation. . Concise review of the disease and treatment options: multiple myeloma. 2011/2012 edition;. Hodgkin Lymphoma. Program Objectives. Brentuximab Vedotin in Hodgkin Lymphoma. Brentuximab Vedotin in Patients With R/R HL. Brentuximab Vedotin: Adverse Events . Nivolumab in Relapsed/Refractory HL. Pembrolizumab in Relapsed/Refractory HL. IWCLL Criteria for Treating CLL. Other Considerations at Relapse. Risk Factors at Relapse. IGHV . Status Affects Clinical Course. Case 1: 65-Year-Old Man. Assessing This Patient's Options. TP53 . Mutation/del(17p) and CIT. Forms a specific and irreversible bond with cysteine-481 in BTK. Highly potent BTK inhibition at . IC. 50. = 0.5 . nM. Orally administered with once daily dosing resulting in 24-hr target inhibition. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.. MSc. University of Tennessee College of . Health Sciences. Memphis, TN. . . Learning Objectives. Upon completion, participants should be able to:. Review treatment regimens for patients with relapsed ALL. T. ransplant . in CR on . B. rentuximab. . V. edotin. : . Allo. . Transplant . or . Maintenance . T. herapy. ?. Anas Younes, M.D.. Memorial Sloan Kettering Cancer Center. Overall Survival. <1990 median 1.9 yrs. Bertrand Coiffier. Service d. ’. Hématologie. Hospices Civils de Lyon. Equipe . « Pathologie des Cellules Lymphoïdes ». UMR 5239 CNRS – UCB – ENS - HCL. The Lymphoma. Study Association. One question, lot of possibilities. Jonathon B. Cohen, MD. Dept of . Hematology. /Medical Oncology. Co-Director . Lymphoma Program. Relapsed aggressive . nhl. associated with shortened survival. Scholar-1 (Crump et al, Blood 2017). Martin et al, Blood 2016.